Core Viewpoint - The Dalian Commodity Exchange has announced adjustments to the designated quality inspection institutions for plywood and fiberboard, establishing new institutions while allowing others to relinquish their qualifications [1] Group 1: Designated Quality Inspection Institutions - The Linyi City Product Quality Supervision and Inspection Institute, Guangxi Zhuang Autonomous Region Forest Products Quality Inspection and Testing Center, and Huace Testing Certification Group Co., Ltd. have been designated as quality inspection institutions for plywood [1] - The China Inspection and Certification Group and SGS (Société Générale de Surveillance) have agreed to relinquish their qualifications as designated quality inspection institutions for plywood and fiberboard [1] - The Linyi Customs Comprehensive Technical Service Center has also agreed to give up its qualification as a designated quality inspection institution for plywood [1]

Group 1 - The Dalian Commodity Exchange has adjusted the designated quality inspection institutions for plywood and fiberboard [1] - The Linyi City Product Quality Supervision and Inspection Institute, Guangxi Zhuang Autonomous Region Forest Products Quality Inspection and Testing Center, and Huace Testing Certification Group Co., Ltd. have been established as designated quality inspection institutions for plywood [1] - The China Inspection and Certification Group Co., Ltd. and SGS-CSTC Standards Technical Services Co., Ltd. have agreed to relinquish their qualifications as designated quality inspection institutions for plywood and fiberboard [1] - The Linyi Customs Comprehensive Technical Service Center has also agreed to relinquish its qualification as a designated quality inspection institution for plywood [1]

截至8月27日收盘，基因测序概念下跌3.38%，位居概念板块跌幅榜前列，板块内，广生堂、睿昂基 因、谱尼测试等跌幅居前，股价上涨的有6只，涨幅居前的有迪安诊断、埃科光电、金域医学等，分别 上涨5.81%、3.67%、2.11%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | F5G概念 | 0.46 | 钛白粉概念 | -3.88 | | 中国AI 50 | 0.36 | 兵装重组概念 | -3.63 | | 共封装光学(CPO) | 0.18 | 天津自贸区 | -3.49 | | 稀土永磁 | 0.10 | 太赫兹 | -3.40 | | 智能音箱 | -0.27 | 基因测序 | -3.38 | | WiFi 6 | -0.46 | 细胞免疫治疗 | -3.29 | | MLOps概念 | -0.49 | 猴痘概念 | -3.25 | | 星闪概念 | -0.62 | 血氧仪 | -3.25 | | MCU芯片 | -0.66 | 幽门螺杆菌概念 | -3.24 | | 国家大基金持股 | -0.72 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [6][23]. Core Views - The company has achieved a year-on-year revenue growth of 6.05% and a net profit growth of 7.03% in the first half of 2025, indicating stable growth and improved business quality [1][3]. - The company is accelerating its overseas strategic acquisitions, including full acquisitions in various regions to enhance its service capabilities and expand into high-value application scenarios [3][4]. - The company has initiated a mid-term dividend distribution, reflecting its commitment to shareholder returns [3]. Financial Performance Summary - In the first half of 2025, the company reported revenues of 2.96 billion yuan and a net profit of 467 million yuan, with significant improvements in cash flow from operating activities [1]. - The revenue breakdown for the first half of 2025 shows double-digit growth in consumer product testing and trade assurance, while other segments are expected to gradually recover [2]. - The company forecasts a steady increase in revenue and net profit from 2025 to 2027, with projected net profits of 1 billion yuan, 1.1 billion yuan, and 1.23 billion yuan respectively [5][24]. Strategic Developments - The company has made several strategic acquisitions, including the full acquisition of Australian analysis and testing firms and agreements to acquire leading service providers in South Africa and Greece, enhancing its global footprint [3][4]. - The company is focusing on high-value areas such as geochemical testing and social responsibility audits, which are expected to contribute to future growth [2][3]. Valuation Metrics - The company maintains a projected PE ratio of 24, 21, and 19 for the years 2025, 2026, and 2027 respectively, indicating a favorable valuation compared to its earnings growth [3][5]. - The company’s market capitalization is approximately 23.54 billion yuan, with a closing price of 13.99 yuan [6][23].

Core Viewpoint - 华测检测's stock price has shown significant growth in recent months, with a year-to-date increase of 15.72% and a 27.18% rise over the past 60 days, indicating strong market performance and investor interest [1]. Financial Performance - For the first half of 2025, 华测检测 reported a revenue of 2.96 billion yuan, representing a year-on-year growth of 6.05%, while the net profit attributable to shareholders was 467 million yuan, up 7.03% compared to the previous year [2]. - Cumulatively, since its A-share listing, 华测检测 has distributed a total of 1.077 billion yuan in dividends, with 436 million yuan distributed over the last three years [3]. Shareholder Structure - As of June 30, 2025, 华测检测 had 81,100 shareholders, an increase of 4.53% from the previous period, with an average of 17,647 circulating shares per shareholder, down 4.34% [2]. - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 269 million shares, which increased by 7.87 million shares from the previous period [3].

事件：公司披露2025 年中报业绩。2025 年上半年公司实现收入29.60 亿元，同比增长6.05%；归母净利 润4.67 亿元，同比增长7.03%；扣非归母净利润4.39 亿元，同比增长9.08%。 业务版图持续拓展，全球化布局加速。25 年上半年，公司完成对ALS 集团中国分支机构澳实分析检测 （广州）公司全资收购；签署对Openview 深圳、香港公司的控股权收购协议；与凯雷集团达成协议， 拟收购南非领先的TICT服务商Safety SA；与希腊Emicert 公司完成控股权收购的协议签署，进一步延伸 公司在材料分析检测、社会责任审核、可持续发展等领域的业务版图，提升公司全球检测服务能力。 投资建议：预计公司2025-2027 年将分别实现归母净利润10.26 亿元、11.51亿元、12.81 亿元，对应EPS 为0.61、0.68、0.76 元，对应PE 为21 倍、19倍、17 倍，维持推荐评级。 风险提示：宏观经济增长不及预期的风险；下游新兴领域发展不及预期的风险；并购整合及投后管理未 达预期的风险；公信力和品牌受不利事件影响的风险；市场竞争加剧的风险等。 Q2 业绩亮眼，消费品测试/贸易保障快 ...

证券研究报告·公司点评报告·专业服务 华测检测（300012） 2025 半年报点评：Q2 归母净利润+9%位于 预告中值，多元化+全球化助力稳健增长 增持（维持） 证券分析师 周尔双 2025 年 08 月 25 日 ◼ Q2 归母净利润+9%位于预告中值，多元化+全球化助力稳健增长 2025 上半年公司实现营业总收入 29.6 亿元，同比增长 6%，归母净利润 4.7 亿元，同比增长 7%，扣非归母净利润 4.4 亿元，同比增长 9%；单 Q2 公 司实现营业总收入 16.7 亿元，同比增长 5%，归母净利润 3.3 亿元，同比 增长 9%，扣非归母净利润 3.1 亿元，同比增长 8%，公司业绩位于预告中 值，符合市场预期，非经常性损益主要为政府补助。分业务（1）生命科学 实现营收 12.7 亿元，同比增长 1%，土壤三普基数较高情况下，通过拓展 宠物食品、海洋监测等细分行业，稳步发展；（2）工业品测试实现营收 6.0 亿元，同比增长 7%；（3）消费品测试实现营收 5.2 亿元，同比增长 13%； （4）贸易保障检测实现营收 4.3 亿元，同比增长 13%；（5）医药行业及其 他实现营收 1.4 亿元， ...

公司点评报告 · 机械设备行业 业绩持续稳健增长，全球化布局加速 ⸺2025 年中报业绩点评 2025 年 08 月 25 日 | 市场数据 | 2025-08-22 | | --- | --- | | 股票代码 | 300012.SZ* | | A 股收盘价(元) | 13.09* | | 上证指数 | 3825.76* | | 总股本（万股） | 168283* | | 实际流通 A 股(万股) | 143177* | | 流通 A 股市值(亿元) | 187* | 相对沪深 300 表现图 2025-08-22 -15% -10% -5% 0% 5% 10% 15% 沪深300 华测检测 核心观点 | 华测检测（股票代码：300012.SZ） | | --- | | 推荐 | | --- | | 维持评级 | 分析师 鲁佩 ：021-20257809 ：lupei_yj @chinastock.com.cn 分析师登记编码：S0130521060001 王霞举 ：021-68596817 ：wangxiaju_yj@chinastock.com.cn 分析师登记编码：S0130524070007 资料来 ...

Market Performance - The professional services sector increased by 2.05% on August 25, with Su Shi Testing leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] Top Gainers in Professional Services - Su Shi Testing (300416) closed at 19.14, up 10.64% with a trading volume of 596,300 shares and a transaction value of 1.125 billion yuan [1] - Zhonggang Tianyuan (002057) closed at 11.45, up 9.99% with a trading volume of 545,700 shares and a transaction value of 612 million yuan [1] - Xince Standard (300938) closed at 25.80, up 7.14% with a trading volume of 184,400 shares and a transaction value of 461 million yuan [1] Other Notable Stocks - Huace Testing (300012) closed at 66.ET, up 6.88% with a trading volume of 1,123,300 shares [1] - Lingdian Youshu (301169) closed at 50.97, up 3.81% with a trading volume of 46,700 shares [1] - Guangdong Jianke (301632) closed at 37.84, up 2.41% with a trading volume of 206,400 shares [1] Market Capital Flow - The professional services sector saw a net inflow of 171 million yuan from institutional investors, while retail investors experienced a net outflow of 35.82 million yuan [2] - The main stocks with significant net inflows included Zhonggang Tianyuan and Huace Testing, while Su Shi Testing and Xince Standard saw net outflows from retail investors [3]

Summary of Centre Testing Intl Group (300012.SZ) Earnings Call Company Overview - **Company**: Centre Testing International Group (CTI) - **Industry**: Testing, Inspection, Certification (TIC) Key Financial Performance - **1H25 Results**: Revenue of Rmb 2,960 million, EBIT of Rmb 493 million, and net profit of Rmb 467 million, representing year-over-year increases of 6%, 10%, and 7% respectively [1] - **2Q25 Results**: Revenue of Rmb 1,673 million, operating profit of Rmb 355 million, and net profit of Rmb 331 million, with year-over-year growth of 5%, 7%, and 9% respectively [1] - **Margins**: Gross profit margin (GPM) at 52%, operating profit margin (OPM) at 21%, and net profit margin (NPM) at 20% [1] Segment Performance - **Life Science**: Revenue growth of 1% in 1H25, but a decline of 3% in 2Q25 due to normalization from a high base in 1H24. Significant drop in soil-census revenue from Rmb 230-250 million in 1H24 to approximately Rmb 20 million in 1H25 [3][7] - **Consumer Goods**: Revenue increased by 13% in 1H25 and 18% in 2Q25, with broad-based growth across sub-lines. Margins under pressure due to increased competition and extended cash collection periods [7] - **Medical**: Revenue growth of 1% in both 1H25 and 2Q25, with profit under pressure from investments and cost growth. Management is focusing on expanding capacity in higher-barrier product lines [7] - **Industrial**: Revenue growth of 7% in 1H25 and 13% in 2Q25, driven by digitalization and carbon-emission certifications [7] - **International Trade**: Revenue growth of 13% in 1H25 and 10% in 2Q25, with ongoing M&A consolidations enhancing local capacity [7] Strategic Initiatives - **M&A Activity**: CTI completed four M&As in 1H25, three of which were overseas, indicating a shift towards accelerating global expansion. The company aims for a 20% mid-term target for overseas revenue contribution [9] - **Cash Flow Improvement**: Operating cash flow surged by approximately 600% year-over-year to Rmb 175 million, reflecting improved cash control and collections [2][10] Future Outlook - **2H25 Guidance**: Expected normalization in life sciences and an accelerating trend in 4Q25 due to M&A consolidations. The company anticipates continued growth in food, consumer goods, and international trade testing [2][8] - **Earnings Projections**: Expected top-line growth of 7% and net profit growth of 10% in 2025E [10] Risks and Challenges - **Key Risks**: Potential damage to company credibility, intensifying pricing competition, greater account receivables risk from the soil census, and potential impairments due to acquisitive growth [13][16] Investment Thesis - **Valuation**: Target price revised to Rmb 14.50 based on a 2026E P/E of 21x, maintaining a Buy rating with an implied upside of 13% [12][17] - **Market Position**: CTI is positioned as a consolidator in the TIC market, with a long-term CAGR of 7% expected for China's TIC market [15]